Case Report: transformation to SCLC from EGFR-mutated squamous cell lung carcinoma during osimertinib treatment
Frontiers in Oncology · 29.07.2026 · 16
DOI: 10.3389/fonc.2026.1822365 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 29.07.2026. Verfasst von Takashi Yamana und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, National Hospital Organization Disaster Medical Center, Tokyo, Japan. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Somatic EGFR mutations are prevalent in lung adenocarcinoma but are exceptionally rare in primary squamous cell carcinoma (SCC). Consequently, while histologic transformation to small cell lung carcinoma (SCLC) is an established resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs) in adenocarcinoma, its occurrence in EGFR-mutated SCC remains virtually uncharacterized, representing a significant knowledge gap in thoracic oncology. Case description We report the case of a 42-year-old male initially diagnosed with stage IIIA EGFR-mutated SCC. Following definitive chemoradiotherapy, the patient experienced disease recurrence and was sequentially treated with erlotinib plus ramucirumab, followed by osimertinib. Upon clinical progression during osimertinib therapy, a repeat biopsy was performed. Pathological and immunohistochemical evaluations revealed a complete phenotypic shift from the initial TTF-1-negative, p40-positive SCC to a TTF-1-positive SCLC, while retaining the original EGFR exon 19 deletion. The patient exhibited a favorable clinical response to a subsequent regimen of carboplatin, etoposide, and durvalumab.
Conclusion
The retention of the EGFR mutation in the present case enabled the definitive diagnosis of histologic transformation from the original squamous cell carcinoma, confirming a shared clonal origin rather than a second primary malignancy. This case underscores the critical clinical necessity of routine resistance monitoring and repeat biopsies with comprehensive histological profiling at the time of TKI failure, regardless of the initial non-small cell lung cancer histology”.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pulmonology, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
- Laboratory and Pathology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
Zitieren
APA
Yamana, T., Hirano, K., Yoshioka, R., Mizuhashi, Y., Tsukamoto, K., Abe, Y., Kodama, H., & Kamimura, M. (2026). Case Report: transformation to SCLC from EGFR-mutated squamous cell lung carcinoma during osimertinib treatment. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1822365
Vancouver
Yamana T, Hirano K, Yoshioka R, Mizuhashi Y, Tsukamoto K, Abe Y, et al. Case Report: transformation to SCLC from EGFR-mutated squamous cell lung carcinoma during osimertinib treatment. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1822365
BibTeX
@article{Yamana2026,
author = {Yamana, Takashi and Hirano, Kazuhiko and Yoshioka, Risa and Mizuhashi, Yusuke and Tsukamoto, Kasumi and Abe, Yukiko and Kodama, Hiroaki and Kamimura, Mitsuhiro},
title = {Case Report: transformation to SCLC from EGFR-mutated squamous cell lung carcinoma during osimertinib treatment},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1822365}
}
EUVIMED